NewCelX Shares Dive 27% After Merger and Reverse Split Amid Strategic Roadmap Launch
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
NewCelX Ltd. (Nasdaq: NCEL) is a publicly traded biotechnology company formed through the merger of Swiss-based NLS Pharmaceutics Ltd. and Israel’s Kadimastem Ltd., effective October 30, 2025. Headquartered in Kloten, Zurich, with research and development operations in Ness Ziona, Israel, the company integrates proprietary cell therapy platforms with small-molecule expertise to develop treatments for central nervous system disorders and metabolic diseases.
Corporate Structure
NewCelX operates with a workforce of 11–50 employees, leveraging expertise in cell biology, pharmacology, and clinical development. Following the merger and a 1-for-10 reverse share split approved on September 29, 2025, its capital structure is as follows:
| Security Type | Outstanding Shares |
|---|---|
| Common shares (CHF 0.05 par value) | 4,558,378 |
| Common shares issuable upon warrants | 1,060,574 |
| Preferred shares (CHF 0.05 par value) | 13,778 |
| Preferred participation certificates | 58,320 |
A capital band permits the issuance of up to 2,859,412 additional common shares, and conditional share capital allows for the future issuance of up to 2,409,412 registered common shares.
Biotechnology by Louis Reed
Recent Developments and News
On September 9, 2025, the U.S. Securities and Exchange Commission declared effective the Form F-4 registration statement, clearing the final U.S. federal regulatory hurdle for the merger. At an extraordinary general meeting on September 29, 2025, shareholders approved both the merger and a 1-for-10 reverse share split. The combined company formally changed its name to NewCelX Ltd. and began trading under the ticker NCEL on October 31, 2025.
On October 30, 2025, NewCelX filed Form 6-K with the SEC to report the closing of the merger. That same day, the company’s warrants matured and were removed from Nasdaq listing and registration under a Form 25-NSE/A filing. On November 3, 2025, NewCelX submitted a Form 6-K outlining a business and strategic roadmap update post-merger, indicating forthcoming operational priorities.
Financial and Strategic Analysis
As of market close on November 3, 2025, NCEL shares were priced at USD 5.2884, reflecting a one-day decline of 27.46 percent on trading volume of 121,147 shares. Detailed financial metrics remain to be disclosed in upcoming filings, but the merger integrates two complementary pipelines:
- Cell Therapy: Initiation of a Phase 2a trial of AstroRx™ in amyotrophic lateral sclerosis, with U.S. clinical site preparations underway.
- Metabolic Diseases: Ongoing development of IsletRx™, a stem cell-derived islet therapy for insulin-dependent diabetes, supported by the BIRD Foundation.
The 1-for-10 reverse split was conducted to align NewCelX’s share structure with Nasdaq Capital Market standards and potentially enhance share price stability. The removal of matured warrants simplifies the capital base and aligns shareholder interests around the core equity.
Market Position and Industry Context
NewCelX operates at the intersection of regenerative medicine and small-molecule therapeutics, a sector demonstrating demand for treatments targeting neurodegenerative and metabolic disorders. Its dual-technology platform differentiates it from peers that concentrate solely on cell therapy or small molecules. By maintaining its Nasdaq listing and U.S. capital market access, the company positions itself to pursue additional funding, partnerships, and clinical milestones in a competitive biotechnology environment.
tl;dr
On November 3, 2025, NewCelX Ltd. shares closed at USD 5.2884, down 27.46 percent on volume of 121,147. The completion of the merger on October 30 merged cell therapy and small-molecule pipelines under Nasdaq ticker NCEL following a 1-for-10 reverse split. Key next steps include initiating a Phase 2a trial of AstroRx™ in ALS and advancing IsletRx™ for Type 1 diabetes, as outlined in the strategic roadmap update filed in Form 6-K.